 |
|
|
| |
High Rates of SVR in Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir + Ribavirin or Ledipasvir/Sofosbuvir + GS-9669 for 8 Weeks
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy).......http://www.natap.org/2013/AASLD/AASLD_30.htm ........100% who received the FDC+the protease (GS9451/Vedroprevir) for 6 weeks achieved SVR4
Sovaldi \ ledipasvir+vedroprevir Study in treatment-experienced gt1 cirrhotics - 8 weeks - (10/08/14)
Eric Lawitz,1 Fred Poordad,1 Robert H. Hyland,2 Jing Wang,2 Phillip S. Pang,2 William T. Symonds,2 John G. McHutchison,2 Fernando E. Membreno1
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 2Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
